Karolinska Institute

So I saw that, got gut microbiota, it's TWIM, but boy, there it ends, man, because it's all biochemistry.

The first author is Andrey Kleschyov, who is also the corresponding author, and Dr. Kleschyov, uh, is at the Karolinska Institute, and we have contributors from the University Medical Center Hamburg, and the Johannes Gutenberg University.

And Kleschyov has been working on these compounds for, for a long, long time.

So we've talked many times here on TWIM about how your gut microbiome plays incredible roles in modulating all kinds of host physiology.

And the research on its effectiveness is, to put it terribly eloquently, Kind of mixed.

The Romanovska Research at Karolinska Institutet, which we covered in depth in an earlier episode of this year's season, randomized working managers into a conventional leadership program and an arts-based alternative and followed them for well over a year.

And the conventional program produced no improvement on the measures that mattered.

On self-awareness, the conventionally trained leaders actually moved in the wrong direction.

We remember how President George Bush Jr. triumphantly declared mission accomplished on May 1st, 2003, on this ship warship after the invasion of Afghanistan which was prompted by the 9-11 attacks.

In a morbid parallel to this announcement the Karolinska Institute in Stockholm granted the 2023 Nobel Prize in Medicine to the COVID-19 vaccines or more specifically for introducing some very specific chemical modifications of the mRNA used in the CV-19 shots.

We had been told on television by our medical authorities that the mRNA in the vaccines was the same as human mRNA and would be degraded within hours in the body as such genetic waste material is supposed to be.

That was another lie.

But first, I want to take a moment to introduce you to our listeners.

So, listeners, Chris is an assistant professor within the Laboratory of Experimental Audiology working on tinnitus within the Department of Physiology and Pharmacology at the Karolinska Institute in Sweden.

Dr. Chris Setteroth He received his PhD from the University of Geneva, and he was awarded the Denver Panard Prize for his PhD work from the University of Geneva.

And during that time, he also contributed to the launch of the startup company Amazentis.

And before joining the faculty where he is today at the Karolinska Institute, he was awarded a Swiss National Foundation Advanced Fellowship for his postdoctoral work conducted at Rockefeller University.

as well as the Wenner-Gren Foundation and Nicholson Postdoctoral Fellowship to support his research at the Karolinska Institute.

And Chris is here with us today, listeners, to talk about his research, but also to tell us about his experiences in life and science.

So Chris, today, we want to get to know you both as a person as well as a scientist.

Maybe you can tell them.

So I went to Sweden with a friend of mine who was the head of clinical genetics at the Karolinska.

And we started looking in these families.

And sure enough, you could tell.

We have been a very academic company.

We've come out of the Karolinska in Stockholm, famous for the Nobel Prize.

So very, very solid science, great scientists.

But as you know, therapeutic development is something very different from sort of academic science.

On the technology

of mRNA side, what we have known and published, actually with Karolinska, as you know, the institute in Sweden that gave the Nobel Prize for Medicine back in 2015, is that with all technology, I cannot speak about all the mRNA companies that have different mRNAs, different lipids and so on, but with all technology, when we inject our mRNA in a muscle, whether it's a COVID shot or flu shot or this cancer treatment, basically the mRNA goes down to your lymph node and enters the APCs, the antigen-presenting cells, which, as you know, are key components of your immune cells.

And the mRNA gets inside the APCs.

This we've demonstrated and proven at the time of Karolinska.

And then it basically translates the message contained in the mRNA inside the APCs, inside your immune cells, and presents it from within.

So we think it's a very important differentiation from most of the previous vaccine in cancer in the field that were made by protein or peptide that basically are made in reactors, are injected in the patient, but they basically turn into the blood because, as you know, recombinant or protein, when you inject them, they just go into your blood and they turn around.